AMNEAL PHARMACEUTICALS, INC. Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-12-31: Other NEO average total compensation $2.98M.
- 2024-12-31: Other NEO average total compensation $2.60M.
- 2023-12-31: Other NEO average total compensation $1.68M.
- 2022-12-31: Other NEO average total compensation $2.35M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $2.98M | $8.87M | $275.71 | $156.35 | $128.00M | Adjusted EBITDA $688.00M | 2026-03-25 | |||
| 2024-12-31 | $2.60M | $4.71M | $173.30 | $118.45 | -$74.00M | $627.00M | 2026-03-25 | |||
| 2023-12-31 | $1.68M | $5.80M | $132.82 | $109.31 | -$49.00M | $558.00M | 2026-03-25 | |||
| 2022-12-31 | $2.35M | -$122.00K | $43.54 | $107.97 | -$255.00M | $514.00M | 2026-03-25 | |||
| 2021-12-31 | $2.42M | $1.42M | $104.81 | $113.11 | $20.00M | $512.00M | 2026-03-25 | |||
| 2024-12-31 | $2.59M | $4.70M | $164.32 | $135.41 | -$74.00M | adjusted EBITDA $627.00M | 2025-03-25 | |||
| 2023-12-31 | $1.68M | $5.80M | $125.93 | $124.97 | -$49.00M | $558.00M | 2025-03-25 | |||
| 2022-12-31 | $2.35M | -$122.00K | $41.29 | $123.43 | -$255.00M | $514.00M | 2025-03-25 | |||
| 2021-12-31 | $2.42M | $1.42M | $99.38 | $129.31 | $20.00M | $512.00M | 2025-03-25 | |||
| 2020-12-31 | $1.92M | $1.99M | $94.81 | $114.32 | $69.00M | $433.00M | 2025-03-25 | |||
| 2023-12-31 | $1.68M | $5.80M | $125.93 | $124.97 | -$89.00M | adjusted EBITDA $558.00M | 2024-03-22 | |||
| 2022-12-31 | $2.35M | -$122.00K | $41.29 | $123.43 | -$255.00M | $514.00M | 2024-03-22 | |||
| 2021-12-31 | $2.42M | $1.42M | $99.38 | $129.31 | $20.00M | $538.00M | 2024-03-22 | |||
| 2020-12-31 | $1.92M | $1.99M | $94.81 | $114.32 | $69.00M | $433.00M | 2024-03-22 | |||
| 2022-12-31 | $2.35M | -$122.00K | $41.29 | $123.43 | -$255.00M | $5.14 | 2023-03-24 | |||
| 2021-12-31 | $2.42M | $1.42M | $99.38 | $129.31 | $20.00M | $5.38 | 2023-03-24 | |||
| 2020-12-31 | $1.92M | $1.99M | $94.81 | $114.32 | $69.00M | $4.33 | 2023-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |